Global R&D Pipeline
My Favorite
Hot Targets:
IL-6R
Back
Total number of drugs
203
Phase II and later clinical stages
20.7%
Involving companies
265
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PN-232 | PN-232 | Small molecule drug | - | IL-23R inhibitors | Protagonist Therapeutics, Inc. | - | Discontinued (in Phase 1) | - | - | - | - | - | - | - | - | - | PN-232 | - | - | detail > | |
| UNI-rhIL-11(Uni-Bio Science Group Ltd.) | UNI-rhIL-11(Uni-Bio Science Group Ltd.) | Interleukins | Hemic and Lymphatic Diseases | IL-11RA stimulants | Uni-Bio Science Group Ltd. | - | Discontinued (in Phase 3) | - | - | - | - | - | - | - | - | - | UNI-rhIL-11(Uni-Bio Science Group Ltd.) | - | - | detail > | |
| Recombinant Human Ciliary Neurotrophic Factor (Southwest China Biotech Base Co Ltd) | Recombinant Human Ciliary Neurotrophic Factor (Southwest China Biotech Base Co Ltd) | Growth factors | Nervous System Diseases Endocrinology and Metabolic Disease Other Diseases | CNTFR agonists | Southwest China Biotech Base Co., Ltd. | - | Discontinued (in IND Application) | Discontinued (in IND Application) | - | - | - | - | - | - | - | - | Recombinant Human Ciliary Neurotrophic Factor (Southwest China Biotech Base Co Ltd) | - | - | detail > | |
| Interleukin-6(Ajinomoto Co., Inc.) | Interleukin-6(Ajinomoto Co., Inc.) | Interleukins | Hemic and Lymphatic Diseases | IL-6R agonists | Ajinomoto Co., Inc. | - | Discontinued (in Phase 2) | - | - | - | - | - | - | - | - | - | Interleukin-6(Ajinomoto Co., Inc.) | - | - | detail > | |
| bacTRL-IL-12 | bacTRL-IL-12 | Gene therapy | Neoplasms | IL-12R stimulants | IQVIA Ltd. | - | Discontinued (in Phase 1) | - | - | - | - | - | - | - | - | - | bacTRL-IL-12 | - | - | detail > | |
| XmAb-662 | XmAb-662 | Fc fusion protein | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases | IL-12R stimulants | Xencor, Inc. | - | Discontinued (in Phase 1) | - | - | - | - | - | - | - | - | - | XmAb-662 | - | - | detail > | |
| Recombinant ciliary neurotrophic factor(Lanzhou Institute of Biological Products Co. Ltd.) | Recombinant ciliary neurotrophic factor(Lanzhou Institute of Biological Products Co. Ltd.) | Growth factors | Endocrinology and Metabolic Disease | CNTFR agonists | Lanzhou Institute of Biological Products Co. Ltd. | - | Discontinued (in IND Application) | Discontinued (in IND Application) | - | - | - | - | - | - | - | - | Recombinant ciliary neurotrophic factor(Lanzhou Institute of Biological Products Co. Ltd.) | - | - | detail > | |
| M-300 | M-300 | Biological products | Digestive System Disorders | CCL20 inhibitors CLDN2 gene inhibitors IL-6RA antagonists | Adhera Therapeutics, Inc. | - | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | - | M-300 | - | - | detail > | |
| Metreleptin/Pramlintide Acetate | Metreleptin/Pramlintide Acetate | Hormone | Endocrinology and Metabolic Disease | CALCR agonists LEPR agonists | Bristol Myers Squibb Co. /Saint Nazaire Assets/ | - | Discontinued (in Phase 2) | - | - | - | - | - | - | - | - | - | Metreleptin/Pramlintide Acetate | - | - | detail > | |
| K-832 | K-832 | Small molecule drug | Immune System Diseases Skin and Musculoskeletal Diseases | IL-1β inhibitors Interleukin-6 receptor antagonists TNF-α inhibitors | Kowa Co., Ltd. | - | Discontinued (in Phase 2) | - | - | - | - | - | - | - | - | - | K-832 | - | - | detail > |
Total 203 data
1
2
3
4
5
6
...
20
21
